Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results

We recently published 10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Hit Highs. Corcept Therapeutics Inc.
Zacks Investment Research on MSN

CORT rises as relacorilant meets OS endpoint in ovarian cancer study

Shares of Corcept Therapeutics CORT were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, ...

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant ...

Is Corcept Therapeutics Incorporated (CORT) the most promising growth stock according to analysts?

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the most promising growth stocks according to analysts. According to ...

CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm

Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL" ...
Yahoo Finance

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

Corcept Therapeutics (CORT) shares soared 13.6% in the last trading session to close at $69.90. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...